Терапия больных немелкоклеточным раком легкого в Российской Федерации: исследование EPICLIN-Lung

Abstract

The first epidemiological observational EPICLIN-Lung study in Russia is aimed at revealing the true incidence and the type of EGFR mutations in the Russian population of patients with non-small cell lung cancer (NSCLC), the connection with the main epidemiological parameters, the treatment approaches and outcomes in real clinical practice. The study was conducted in 33 oncology centers across 24 Russian regions; the study included 838 patients with histologically confirmed NSCLC. Most patients (63.2%) presented with advanced disease (stage III-IV patients) and Squamous-cell carcinoma (54.3%) and adenocarcinoma (31%) were the most prevalent histology types of NSCLC. Epidemiology of EGFR mutations in this NSCLC cohort was similar to other studies of NSCLC in Caucasian populations. EGFR mutations were identified in 10.1% of NSCLC patients included in this study, most of them were women (69.4%) and associated with adenocarcinoma histologically (58.8%) and 71.8% of these patients were never-smokers. The presence of EGFR mutations in tumor indicated the low risk for progression. The results of EPICLIN-Lung study would contribute to a better understanding of prognostic and predictive factors of NSCLC in Russian populations and that would help to choose the optimal therapy in routine clinical practice.